Navigation Links
Gene Therapy - Technologies, Markets and Companies
Date:11/30/2011

cancer gene therapy 250

Tumor suppressor gene therapy 250

P53 gene therapy 250

BRIT1 gene therapy 251

Nitric oxide-based cancer gene therapy 251

Nitric oxide synthase II DNA injection 251

Gene therapy for radiosensitization of cancer 251

Gene therapy of cancer of selected organs 252

Gene therapy for bladder cancer 252

Gene therapy for glioblastoma multiforme. 252

Adenoviral vectors for treatment of brain tumors 254

Antiangiogenic gene therapy 254

Autophagy induced by conditionally replicating adenoviruses 255

Baculovirus vector for diphtheria toxin gene therapy 255

Cerepro® (sitimagene ceradenovec) 255

Gene therapy targeting hepatocyte growth factor 256

Genetically engineered MSCs for gene delivery to intracranial gliomas 256

Intravenous gene delivery with nanoparticles into brain tumors 256

Ligand-directed delivery of dsRNA molecules targeted to EGFR 256

RNAi gene therapy of brain cancer 257

Targeting normal brain cells with an AAV vector encoding interferon-? 257

Viral oncolysis of brain tumors 258

Gene therapy for breast cancer 258

Gene vaccine for breast cancer 259

Recombinant adenoviral ErbB-2/neu vaccine 259

Gene Therapy for ovarian cancer 260

Gene therapy for malignant melanoma 261

Gene therapy of lung cancer 263

Intravenous nanoparticle formulation for delivery of FUS1 gene 263

Aerosol gene delivery for lung cancer 263

Gene therapy for cancer of prostate 264

Experimental studies 264

Nanoparticle-based gene therapy for prostate cancer 264

Tumor suppressor gene therapy in prostate cancer 264

Vaccines for prostate cancer 265

Clinical trials 265

Gene therapy of head and neck cancer 266

Adenoviral vector based P53 gene therapy 266

Gene therapy of pancreatic cancer 266

Rexin-G? for targeted
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
2. Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
3. Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
4. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
5. New Findings Reported by TJ Gan and Authors from Duke Anesthesiology Demonstrate Efficacy of Cheetah Medicals NICOM® Bioreactance® Technology to Guide Goal Directed Intraoperative Therapy
6. Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
7. KGI Professor Awarded Patent for Stem-Cell Therapy Aiding Heart-attack Patients
8. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
9. EGEN, Inc. Collaborates With Nanotechnology Characterization Laboratory on Brain Cancer Therapy
10. SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
11. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 19, 2014 BioPlus ... specialty pharmacies, announces the promotion of Nick Maroulis, Pharm.D. ... Specialty Pharmacy Services. , In this position, Dr. ... while also managing the directors of our multi-site pharmacies ... BioPlus since 1997 and during that time he has ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 19, 2014 ... biomaterial market will grow at a 12 percent compound ... a result of the aging population and the increasing ... Latin America will also spur demand ... results of dental implant and periodontal treatments. ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 LayerBio ... for ophthalmology and wound care. The National Eye Institute ... awarded LayerBio a Phase I SBIR grant to develop ... Cataracts are the most common cause of vision loss ... of blindness worldwide. According to Dr. Ken Mandell, LayerBio’s ...
(Date:12/19/2014)... In contrast to traditional LED lights ... colors, Valoya uses proprietary LED technology to incorporate their ... uniformity which is critical in low proximity installations. The ... throughout its lifetime which is up to four times ... "The investment cost was clearly higher when compared to ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... Epeius Biotechnologies ( www.epeiusbiotech.com ) announced today that the U.S. ... anti-cancer agent, Rexin-G , the first, and so far ... out and destroy metastatic cancer. According to Dr. Maria Gordon, ... of clinical development, is that the Rexin-G product, with its ...
... ("ShengdaTech" or the "Company") (NASDAQ: SDTH ), ... China, today announced that Mr. Xiangzhi Chen, the Company,s ... CFO and Mr. A. Carl Mudd, lead independent director, ... Conference to be held from March 6-8, 2011 in ...
... 2011 CSL Behring announces a ... released in conjunction with Rare Disease Day 2011 , ... their impact on people,s lives. The Dialogue spanned ... important information and ideas for patients, caregivers and healthcare providers. ...
Cached Biology Technology:Epeius Biotechnologies' REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA 2ShengdaTech to Present at Rodman & Renshaw Annual China Investment Conference in Shanghai 2Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 2Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 3Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 4Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 5
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... and, new research shows, an infrared laser can make a ... and Vanderbilt University found that pulsed light can pace contractions ... the tissue. The work, "Optical pacing of the embryonic heart," ... Nature Photonics on Aug. 15, 2010. According to ...
... 27 BIO-key International, Inc. (OTC Bulletin Board: http://photos.prnewswire.com/prnh/20050509/BIOKEYLOGO ) ... What: , BIO-key International, Inc. Second Quarter ... Thursday, July 29, 2010 - 10:00 a.m. Eastern Time ... Live via phone by dialing 800-860-2442 and asking for the BIO-key call ...
... 13, 2010The easy accessibility of the eye and the ... offer hope for using gene therapy to provide long-term ... Human Gene Therapy, a peer-reviewed journal published by Mary ... replacement of a human gene to preserve photoreceptor function ...
Cached Biology News:A heart beats to a different drummer 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 3Promising results of gene therapy to treat diseases of the eye 2
...
A camera based compact unit for high speed scanning of 2D barcoded tubes in a cluster rack. This reader has been designed to read both 96 and 48 tube rack configurations and be compatible with common...
...
... enzyme that catalyzes the conversion,of starch ... maltotriose and,dextrins. The level of a-amylase ... are of clinical importance,1-3 while plant ... industry.4, The EnzChek Amylase Assay Kit ...
Biology Products: